Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial

or

Watchlist | Portfolio

quotes
- Price Overview
- Performance Report
charts
- Interactive Chart
- Snapshot Chart
technicals
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Phio Pharmaceuticals Corp (PHIO)

Phio Pharmaceuticals Corp (PHIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules PR Newswire - Fri Jun 2, 2023

/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...

Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute PR Newswire - Wed May 24, 2023

/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...

Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL™ Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells PR Newswire - Thu May 18, 2023

/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...

Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas PR Newswire - Tue May 16, 2023

/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...

Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update PR Newswire - Thu May 11, 2023

/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...

Phio Pharmaceuticals Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire - Thu Apr 20, 2023

/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...

Phio Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire - Tue Apr 18, 2023

/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...

Phio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-Enhanced in vivo Anti-Tumor Efficacy of PD-1/CTLA-4 Dual-Targeting INTASYL PR Newswire - Tue Apr 18, 2023

/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...

Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-Tumor Immunity PR Newswire - Mon Apr 17, 2023

/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...

Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update PR Newswire - Wed Mar 22, 2023

/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...

Want to use this as
your default charts setting?

Save this setup as a Chart Templates

Switch the Market flag

for targeted data from your country of choice.

Open the menu and switch the
Market flag for targeted data from your country of choice.

Want Streaming Chart Updates?

Switch your Site Preferences
to use Interactive Charts

Need More Chart Options?

Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar